Related Experiment Videos
Magaly Vialon1, Rachel Desailloud2, Philippe Caron1
1Service endocrinologie et maladies métaboliques, pôle cardio-vasculaire et métabolique, CHU Larrey-Rangueil, Toulouse, France.
Annales D'Endocrinologie
|October 14, 2019
Summary
Multiple Endocrine Neoplasia Type 1 (NEM1), caused by menin gene mutations, leads to endocrine tumors. Management requires considering NEM1
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Multiple Endocrine Neoplasia Type 1 (NEM1) is an autosomal dominant inherited disorder.
- It is associated with mutations in the menin gene, affecting approximately 1 in 30,000 individuals.
- NEM1 is characterized by a high penetrance, though genotype-phenotype correlations are not established.
Purpose of the Study:
- To outline the key features of Multiple Endocrine Neoplasia Type 1.
- To highlight the specific clinical manifestations and management considerations for NEM1.
- To differentiate NEM1 from sporadic forms of endocrine tumors.
Main Methods:
- Review of existing literature on Multiple Endocrine Neoplasia Type 1.
- Analysis of clinical characteristics and genetic basis of NEM1.
- Comparison of NEM1 pathologies with sporadic endocrine neoplasias.
Main Results:
- NEM1 primarily involves tumors of the parathyroid, endocrine pancreas, pituitary, and adrenal glands.
- Associated conditions include carcinoid tumors, breast cancer, and skin lesions.
- NEM1 cases often present with earlier onset, multiple lesions within glands, and multifocal disease compared to sporadic tumors.
Conclusions:
- Effective management of NEM1 necessitates recognizing its unique features.
- Treatment strategies must be tailored to address the specific challenges of this hereditary syndrome.
- Understanding these differences is crucial for optimal patient outcomes in NEM1.